Unit
Medizinische Onkologie und Hämatologie
ONKO · Dept. I
Der Mystiker aus Nazaret
Renz M. Der Mystiker aus Nazaret - Jesuanische Spiritualität. 2022.
Jan 25, 2022Der Mystiker aus Nazaret
Jan 25, 2022
Renz Monika
Current status and future outlooks on therapeutic drug monitoring of fluorouracil.
Schmulenson E, Zimmermann N, Mikus G, Jörger M, Jaehde U. Current status and future outlooks on therapeutic drug monitoring of fluorouracil. Expert Opin Drug Metab Toxicol 2022; 17:1407-1422.
Jan 24, 2022Current status and future outlooks on therapeutic drug monitoring of fluorouracil.
Jan 24, 2022Expert Opin Drug Metab Toxicol 2022; 17:1407-1422
Schmulenson Eduard, Zimmermann Nigina, Mikus Gerd, Jörger Markus, Jaehde Ulrich
Treatment and follow-up of rare testis tumours.
Fankhauser C, Grogg J, Rothermundt C, Clarke N. Treatment and follow-up of rare testis tumours. J Cancer Res Clin Oncol 2022; 148:667-671.
Jan 20, 2022Treatment and follow-up of rare testis tumours.
Jan 20, 2022J Cancer Res Clin Oncol 2022; 148:667-671
Fankhauser Christian Daniel, Grogg Josias Bastian, Rothermundt Christian, Clarke Noel William
Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
Gerber B, Untch M, Kast K, Jackisch C, Thomalla J, Seither F, Blohmer J, Rhiem K, Fasching P, Nekljudova V, Loibl S, Hahn M, Klare P, Ataseven B, Schneeweiss A, Möbus V, Golatta M, Tesch H, Krug D, Hanusch C, Denkert C, Lübbe K, Heil J, Huober J, Kühn T. Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. Cancers (Basel) 2022; 14
Jan 20, 2022Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial
Jan 20, 2022Cancers (Basel) 2022; 14
Gerber Bernd, Untch Michael, Kast Karin, Jackisch Christian, Thomalla Jörg, Seither Fenja, Blohmer Jens-Uwe, Rhiem Kerstin, Fasching Peter A, Nekljudova Valentina, Loibl Sibylle, Hahn Markus, Klare Peter, Ataseven Beyhan, Schneeweiss Andreas, Möbus Volker, Golatta Michael, Tesch Hans, Krug David, Hanusch Claus, Denkert Carsten, Lübbe Kristina, Heil Jörg, Huober Jens, Kühn Thorsten
Navigating Difficult Waters: A Cancer Journey.
Omlin A, Nestor K. Navigating Difficult Waters: A Cancer Journey. J Clin Oncol 2022; 40:911-914.
Jan 7, 2022Navigating Difficult Waters: A Cancer Journey.
Jan 7, 2022J Clin Oncol 2022; 40:911-914
Omlin Aurelius, Nestor Karen
Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG).
Seidel C, Hentrich M, Zschäbitz S, Paffenholz P, Heidenreich A, Nestler T, Tran B, Fischer S, Daugaard G, Ochsenreither S, Brito M, Zengerling F, Schwab C, Bokemeyer C, Oing C. Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). World J Urol 2022; 40:355-361.
Jan 7, 2022Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG).
Jan 7, 2022World J Urol 2022; 40:355-361
Seidel Christoph, Hentrich Marcus, Zschäbitz Stefanie, Paffenholz Pia, Heidenreich Axel, Nestler Tim, Tran Ben, Fischer Stefanie, Daugaard Gedske, Ochsenreither Sebastian, Brito Margarida, Zengerling Friedemann, Schwab Constantin, Bokemeyer Carsten, Oing Christoph
Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
van Rees D, Saura C, Di Cosimo S, Huober J, Roylance R, Kim S, Kuijpers T, van Bruggen R, K van den Berg T, Guillaume S, Izquierdo M, El-Abed S, Bouti P, Klein B, Verkuijlen P, van Houdt M, Schornagel K, Tool A, Venet D, Sotiriou C, Matlung H. Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex. J Immunother Cancer 2022; 10
Jan 1, 2022Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex
Jan 1, 2022J Immunother Cancer 2022; 10
van Rees Dieke J, Saura Cristina, Di Cosimo Serena, Huober Jens, Roylance Rebecca, Kim Sung-Bae, Kuijpers Taco W, van Bruggen Robin, K van den Berg Timo, Guillaume Sébastien, Izquierdo Miguel, El-Abed Sarra, Bouti Panagiota, Klein Bart, Verkuijlen Paul J H, van Houdt Michel, Schornagel Karin, Tool Anton T J, Venet David, Sotiriou Christos, Matlung Hanke L
Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Blohmer J, Jackisch C, Rhiem K, Solbach C, Hanusch C, Seither F, Denkert C, Engels K, Nekljudova V, Loibl S, Thill M, Huober J, Link T, Reinisch M, Just M, Untch M, Stötzer O, Fasching P, Schneeweiss A, Wimberger P, Seiler S, GBG and AGO-B. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial. JAMA Oncol 2022; 8:1010-1018.
Jan 1, 2022Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial
Jan 1, 2022JAMA Oncol 2022; 8:1010-1018
Blohmer Jens-Uwe, Jackisch Christian, Rhiem Kerstin, Solbach Christine, Hanusch Claus, Seither Fenja, Denkert Carsten, Engels Knut, Nekljudova Valentina, Loibl Sibylle, Thill Marc, Huober Jens, Link Theresa, Reinisch Mattea, Just Marianne, Untch Michael, Stötzer Oliver, Fasching Peter A, Schneeweiss Andreas, Wimberger Pauline, Seiler Sabine, GBG and AGO-B
[How Myelodysplastic Syndrome is Diagnosed].
Silzle T. [How Myelodysplastic Syndrome is Diagnosed]. Ther Umsch 2022; 78:77-85.
Jan 1, 2022[How Myelodysplastic Syndrome is Diagnosed].
Jan 1, 2022Ther Umsch 2022; 78:77-85
Silzle Tobias
Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
Daly M, Singh N, Ismaila N, Antonoff M, Arenberg D, Bradley J, David E, Detterbeck F, Früh M, Gubens M, Moore A, Padda S, Patel J, Phillips T, Qin A, Robinson C, Simone C. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol 2021; 40:1356-1384.
Dec 22, 2021Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline.
Dec 22, 2021J Clin Oncol 2021; 40:1356-1384
Daly Megan E, Singh Navneet, Ismaila Nofisat, Antonoff Mara B, Arenberg Douglas A, Bradley Jeffrey, David Elizabeth, Detterbeck Frank, Früh Martin, Gubens Matthew A, Moore Amy C, Padda Sukhmani K, Patel Jyoti D, Phillips Tanyanika, Qin Angel, Robinson Clifford, Simone Charles B
What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
Pizzamiglio S, Huober J, Ellard S, Rimm D, Gombos A, Daidone M, Verderio P, Tagliabue E, Di Cosimo S, Nuciforo P, Bajji M, Cosentino G, Ciniselli C, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Iorio M. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study. Cancer Med 2021; 11:332-339.
Dec 17, 2021What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
Dec 17, 2021Cancer Med 2021; 11:332-339
Pizzamiglio Sara, Huober Jens, Ellard Susan L, Rimm David L, Gombos Andrea, Daidone Maria Grazia, Verderio Paolo, Tagliabue Elda, Di Cosimo Serena, Nuciforo Paolo, Bajji Mohammed, Cosentino Giulia, Ciniselli Chiara M, De Cecco Loris, Cataldo Alessandra, Plantamura Ilaria, Triulzi Tiziana, El-Abed Sarra, Wang Yingbo, Iorio Marilena V
Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.
Fankhauser C, Christiansen A, Rothermundt C, Cathomas R, Wettstein M, Grossmann N, Grogg J, Templeton A, Hirschi-Blickenstorfer A, Lorch A, Gillessen S, Moch H, Beyer J, Hermanns T. Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. Br J Cancer 2021; 126:1140-1144.
Dec 15, 2021Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours.
Dec 15, 2021Br J Cancer 2021; 126:1140-1144
Fankhauser Christian D, Christiansen Ailsa J, Rothermundt Christian, Cathomas Richard, Wettstein Marian S, Grossmann Nico C, Grogg Josias B, Templeton Arnoud J, Hirschi-Blickenstorfer Anita, Lorch Anja, Gillessen Silke, Moch Holger, Beyer Joerg, Hermanns Thomas
Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
Mc Laughlin A, Schmulenson E, Teplytska O, Zimmermann S, Opitz P, Groenland S, Huitema A, Steeghs N, Müller L, Fuxius S, Illerhaus G, Jörger M, Mayer F, Fuhr U, Holdenrieder S, Hempel G, Scherf-Clavel O, Jaehde U, Kloft C, For The On-Target Study Consortium. Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol. Cancers (Basel) 2021; 13
Dec 14, 2021Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol.
Dec 14, 2021Cancers (Basel) 2021; 13
Mc Laughlin Anna M, Schmulenson Eduard, Teplytska Olga, Zimmermann Sebastian, Opitz Patrick, Groenland Stefanie L, Huitema Alwin D R, Steeghs Neeltje, Müller Lothar, Fuxius Stefan, Illerhaus Gerald, Jörger Markus, Mayer Frank, Fuhr Uwe, Holdenrieder Stefan, Hempel Georg, Scherf-Clavel Oliver, Jaehde Ulrich, Kloft Charlotte, For The On-Target Study Consortium
Hyper- or Pseudoprogression? A Case Report of MSI-High Metastatic Colorectal Cancer
Schuler A, Omlin A, Husarik D, Denecke B, Rothermundt C. Hyper- or Pseudoprogression? A Case Report of MSI-High Metastatic Colorectal Cancer. Annals of Clinical Case Reports 2021
Dec 13, 2021Hyper- or Pseudoprogression? A Case Report of MSI-High Metastatic Colorectal Cancer
Dec 13, 2021Annals of Clinical Case Reports 2021
Schuler Alexandra, Omlin Aurelius, Husarik Daniela B., Denecke Barbara, Rothermundt Christian
Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer.
Bösch M, Baty F, Albrich W, Flatz L, Rodriguez R, Rothschild S, Jörger M, Früh M, Brutsche M. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer. Oncoimmunology 2021; 10:1988403.
Dec 10, 2021Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer.
Dec 10, 2021Oncoimmunology 2021; 10:1988403
Bösch Maximilian, Baty Florent, Albrich Werner, Flatz Lukas, Rodriguez Regulo, Rothschild Sacha I, Jörger Markus, Früh Martin, Brutsche Martin H
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörger M, Risch M, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. J Cancer Res Clin Oncol 2021; 148:647-656.
Dec 7, 2021Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Dec 7, 2021J Cancer Res Clin Oncol 2021; 148:647-656
Purde Mette-Triin, Niederer Rebekka, Wagner Nikolaus, Diem Stefan, Berner Fiamma, Hasan Ali Omar, Hillmann Dorothea, Bergamin Irina, Jörger Markus, Risch Martin, Niederhauser Christoph, Lenz Tobias L, Früh Martin, Risch Lorenz, Semela David, Flatz Lukas
Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV
Damas J, Hundsberger T, Di Benedetto C, Rossi S, Hasse B, Schlosser L, Du Pasquier R, Darling K, Cavassini M, Schmid P, Assal F, Ledergerber B, Nadin I, Tarr P, Stoeckle M, Kunze U, Hauser C, Gutbrod K, Calmy A, and the NAMACO study group. Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV. AIDS 2021; 35:2469-2480.
Dec 1, 2021Neurocognitive course at 2-year follow-up in a Swiss cohort of people with well-treated HIV
Dec 1, 2021AIDS 2021; 35:2469-2480
Damas José, Hundsberger Thomas, Di Benedetto Caroline, Rossi Stefania, Hasse Barbara, Schlosser Ladina, Du Pasquier Renaud, Darling Katharine E A, Cavassini Matthias, Schmid Patrick, Assal Frédéric, Ledergerber Bruno, Nadin Isaure, Tarr Philip E, Stoeckle Marcel, Kunze Ursi, Hauser Christoph, Gutbrod Klemens, Calmy Alexandra, and the NAMACO study group
Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Berner F, Niederer R, Luimstra J, Pop O, Jochum A, Purde M, Hasan Ali O, Bomze D, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Dubbelaar M, Abdou M, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser D, Ludewig B, Driessen C, Jörger M, Früh M, Jochum W, Cozzio A, Rammensee H, Walz J, Neefjes J, Flatz L. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. Oncoimmunology 2021; 10:2006893.
Nov 27, 2021Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival.
Nov 27, 2021Oncoimmunology 2021; 10:2006893
Berner Fiamma, Niederer Rebekka, Luimstra Jolien J, Pop Oltin Tiberiu, Jochum Ann-Kristin, Purde Mette-Triin, Hasan Ali Omar, Bomze David, Bauer Jens, Freudenmann Lena Katharina, Marcu Ana, Wolfschmitt Eva-Maria, Haen Sebastian, Gross Thorben, Dubbelaar MariLisa, Abdou Marie-Therese, Baumgaertner Petra, Appenzeller Christina, Cicin-Sain Caroline, Lenz Tobias, Speiser Daniel E, Ludewig Burkhard, Driessen Christoph, Jörger Markus, Früh Martin, Jochum Wolfram, Cozzio Antonio, Rammensee Hans-Georg, Walz Juliane, Neefjes Jacques, Flatz Lukas
Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
Vogl U, Mottet N, Padhani A, Roach M, Rubin M, Sartor O, Small E, Smith M, Soule H, Sydes M, Tombal B, Omlin A, Gillessen S, James N, Halabi S, Beer T, Davis I, Shore N, Sweeney C, Ost P, Attard G, Bossi A, de Bono J, Drake C, Efstathiou E, Fanti S, Fizazi K, APCCC 2019 expert panel. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. Eur J Cancer 2021; 160:24-60.
Nov 26, 2021Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings
Nov 26, 2021Eur J Cancer 2021; 160:24-60
Vogl Ursula M, Mottet Nicolas, Padhani Anwar R, Roach Mack, Rubin Mark, Sartor Oliver, Small Eric, Smith Matthew R, Soule Howard, Sydes Matthew R, Tombal Bertrand, Omlin Aurelius, Gillessen Silke, James Nicolas, Halabi Susan, Beer Tomasz M, Davis Ian D, Shore Neal D, Sweeney Christopher J, Ost Piet, Attard Gerhardt, Bossi Alberto, de Bono Johann, Drake Charles G, Efstathiou Eleni, Fanti Stefano, Fizazi Karim, APCCC 2019 expert panel
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo R, Han J, Dafni U, Cho B, Yeo C, Nadal E, Carcereny E, de Castro J, Sala M, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R, Peters S, ETOP 10-16 BOOSTER Collaborators. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial. Ann Oncol 2021; 33:181-192.
Nov 26, 2021A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Nov 26, 2021Ann Oncol 2021; 33:181-192
Soo R A, Han J-Y, Dafni U, Cho B C, Yeo C M, Nadal E, Carcereny E, de Castro J, Sala M A, Bernabé R, Coate L, Provencio Pulla M, Garcia Campelo R, Cuffe S, Hashemi S M S, Früh M, Massuti B, Garcia-Sanchez J, Dómine M, Majem M, Sanchez-Torres J-M, Britschgi C, Pless M, Dimopoulou G, Roschitzki-Voser H, Ruepp B, Rosell R, Stahel R A, Peters S, ETOP 10-16 BOOSTER Collaborators